mGluR1 Inhibitor

DFMTI (MK5435) is a blood-brain barrier-penetrant mGluR1 inhibitor. DFMTI abolishes the tobacco mosaic virus (TMV) resistance phenotype of NbAS-B-overexpressing plants by inhibiting glutamate production required for the activation of the Salicylic acid (HY-B0167) pathway. DFMTI disrupts prepulse inhibition in rats. DFMTI can be used in research related to psychiatric disorders and tobacco mosaic virus infection.

FITM is a negative allosteric modulator of mGlu1 receptor with a K_i of 2.5 nM.

FTIDC is an orally active, noncompetitive, selective allosteric metabotropic glutamate receptor (mGluR) 1 antagonist with an IC₅₀ of 5.8 nM for human mGluR1a. FTIDC has no species differences in its antagonistic activity on recombinant human, mouse, and rat mGluR1.

DFMTI (Standard) (MK5435 (Standard)) is the analytical standard of DFMTI (HY-100404). This product is intended for research and analytical applications. DFMTI is a blood-brain barrier-penetrant mGluR1 inhibitor. DFMTI abolishes the tobacco mosaic virus (TMV) resistance phenotype of NbAS-B-overexpressing plants by inhibiting glutamate production required for the activation of the Salicylic acid (HY-B0167) pathway. DFMTI disrupts prepulse inhibition in rats. DFMTI can be used in research related to psychiatric disorders and tobacco mosaic virus infection.